血清miR-200a、miR-152水平与妊娠滋养细胞肿瘤化疗患者预后的关系

doi:10.3969/j.issn.1006-5725.2023.20.012

Abstract

Abstract:

Objective This study mainly explores the role of serum microRNA-200a （miR-200a） and microRNA-152 （miR-152） in gestational trophoblastic tumors （GTN） prognosis. Methods One-hundred GTN chemotherapy patients who treated in our hospital were collected as the observation group， according to the efficacy of chemotherapy， patients were divided into the good prognosis group （80 cases） and the poor prognosis group （20 cases）； 103 healthy women who underwent physical examination were collected as the control group. Real-time fluorescence quantitative PCR method was applied to detect the expression levels of miR-200a and miR-152 in serum. Results The serum miR-200a expression level in the observation group was higher than that in the control group， while the miR-152 expression level was lower than that in the control group （P < 0.05）. With the prolongation of chemotherapy time， the expression level of miR-200a in the serum of the good prognosis group and the poor prognosis group decreased sequentially， while the expression level of miR-152 increased sequentially （P < 0.05）. The expression level of miR-200a in the serum of the poor prognosis group before and after chemotherapy were higher than that of the good prognosis group， while the expression level of miR-152 was lower than that of the good prognosis group （P < 0.05）. There was a statistically significant difference in the International Federation of Obstetrics and Gynecology （FIGO） prognosis score and pre chemotherapy blood HCG levels between the group with good prognosis and the group with poor prognosis （P < 0.05）. The AUC of predicting poor prognosis in GTN chemotherapy patients with serum miR-200a and miR-152 expression levels before chemotherapy alone and in combination were 0.793， 0.844， and 0.887， respectively. MiR-200a， miR-152， and FIGO prognosis scores≥7 are associated with poor prognosis in GTN chemotherapy patients （P < 0.05）. Conclusion High expression of miR-200a and low expression of miR-152 before chemotherapy may be associated with poor prognosis in GTN chemotherapy patients， which can provide reference for the evaluation of chemotherapy prognosis.

Key words: gestational trophoblastic neplasma, chemotherapy, micro RNA-200a, micro RNA-152, prognosis

CLC Number:

R737.33

Jing WU,Yan ZHAO,Ke ZHANG,Jing YANG,Shengjun. MENG. The relationship between serum levels of miR⁃200a and miR⁃152 and the prognosis of patients with gestational trophoblastic neoplasia undergoing chemotherapy[J]. The Journal of Practical Medicine, 2023, 39(20): 2623-2628.

Figures/Tables 5

Tab.1

Fig.1

Tab.2

Tab.3

Tab.4

References 25

1	LUKINOVIC N， MALOVRH E P， TAKAC I， et al. Advances in diagnostics and management of gestational trophoblastic disease［J］. Radiol Oncol， 2022， 56（4）：430-439.
2	WANG Y X， CUI L， WU W B， et al. Downregulation of PDCD4 by deSUMOylation associates with the progression of gestational trophoblastic disease［J］. Placenta， 2022， 130（1）：17-24.
3	SILVA A L M D， MONTEIRO K D N， SUN S Y， et al. Gestational trophoblastic neoplasia： Novelties and challenges［J］. Placenta， 2021， 116（1）：38-42.
4	吴齐斌，宋一一，祝建芳，等. Nanog和p53蛋白在妊娠滋养细胞疾病中的表达及临床意义［J］. 中国妇产科临床杂志， 2020， 21（2）：179-183.
5	WU G M， JIN Y， CAO Y M， et al. The diagnostic value and regulatory mechanism of miR-200a targeting ZEB1 in pregnancy-induced hypertension［J］. Hypertens Pregnancy， 2020， 39（3）：243-251.
6	ZHANG L， YUAN J M， ZHAO R H， et al. Correlation of MiR-152 expression with VEGF expression in placental tissue of preeclampsia rat and its influence on apoptosis of trophoblast cells［J］. Eur Rev Med Pharmacol， 2019， 23（9）：3553-3560.
7	NGAN H Y S， SECKL M J， BERKOWITZ R S， et al. Diagnosis and management of gestational trophoblastic disease： 2021 update［J］. Int J Gynaecol Obstet， 2021， 155（1）：86-93.
8	BUZA N. Gestational trophoblastic disease： contemporary diagnostic approach［J］. Surg Pathol Clin， 2022， 15（2）：197-218.
9	HOEIJMAKERS Y M， SIMONS M， BULTEN J， et al. PD-L1 in gestational trophoblastic disease： an antibody evaluation［J］. Acta Obstet Gynecol Scand， 2022， 101（9）：1007-1016.
10	陈梦捷，梁月娟，万兵，等. 高预后评分妊娠滋养细胞肿瘤患者化疗疗效及耐药因素分析［J］. 中华肿瘤防治杂志， 2020， 27（4）：310-315.
11	JIN M， XU Q， LI J， et al. Micro-RNAs in human placenta： tiny molecules， immense power［J］. Molecules， 2022， 27（18）：5943-5961.
12	陈希妍，马彦娟，牛丽丹，等. 缺糖缺氧心肌细胞中miRNA-155对Notch信号通路及自噬和凋亡的影响［J］. 实用医学杂志， 2021， 37（3）：304-307.
13	NING W， WU B， CHEN Y， et al. Role of microRNAs regulating trophoblast cell function in the pathogenesis of pre‑eclampsia （Review）［J］. Exp Ther Med， 2022， 25（1）：50-58.
14	YE Z， WANG S， HUANG X， et al. Plasma exosomal miRNAs associated with metabolism as early predictor of gestational diabetes mellitus［J］. Diabetes， 2022， 71（11）：2272-2283.
15	HAYDER H， SHAN Y， CHEN Y， et al. Role of microRNAs in trophoblast invasion and spiral artery remodeling： Implications for preeclampsia［J］. Front Cell Dev Biol， 2022， 10（1）：1-24.
16	LIANG L， CHEN Y， WU C， et al. MicroRNAs： key regulators of the trophoblast function in pregnancy disorders［J］. J Assist Reprod Genet， 2023， 40（1）：3-17.
17	LI P， LIU X， XING W， et al. Exosome-derived miR-200a promotes esophageal cancer cell proliferation and migration via the mediating Keap1 expression［J］. Mol Cell Biochem， 2022， 477（4）：1295-1308.
18	KLICKA K， GRZYWA T M， MIELNICZUK A， et al. The role of miR-200 family in the regulation of hallmarks of cancer［J］. Front Oncol， 2022， 12（1）：1-37.
19	KHALIL E H， SHAKER O G， HASONA N A. Impact of rs2107425 polymorphism and expression of lncH19 and miR-200a on the susceptibility of colorectal cancer［J］. Indian J Clin Biochem， 2023， 38（3）：331-337.
20	刘莹，刘海娟，黄志娟. miR-200a-3p靶向转甲状腺素蛋白对妊娠期高血压疾病滋养细胞生物学行为的影响［J］. 广西医科大学学报， 2021， 38（1）：1-8.
21	LIN T， YU C C， LIAO Y W， et al. miR-200a inhibits proliferation rate in drug-induced gingival overgrowth through targeting ZEB2［J］. J Formos Med Assoc， 2020， 119（8）：1299-1305.
22	HUANG Y， BAO T， LI Z， et al. Function of miR-200a in proliferation and apoptosis of non-small cell lung cancer cells［J］. Oncol Lett， 2020， 20（2）：1256-1262.
23	TIAN Y， LI L， LIN G， et al. lncRNA SNHG14 promotes oncogenesis and immune evasion in diffuse large-B-cell lymphoma by sequestering miR-152-3p［J］. Leuk Lymphoma， 2021， 62（7）：1574-1584.
24	WANG Y， WU X Q， CAI J R， et al. SIRT7 silencing by miR-152-3p confers cell apoptosis and renal functional impairment induced by renal ischaemia/reperfusion injury［J］. Int Urol Nephrol， 2023， 55（2）：367-376.
25	FABOVÁ Z， KISLÍKOVÁ Z， LONCOVÁ B， et al. MicroRNA miR-152 can support ovarian granulosa cell functions and modify apigenin actions［J］. Domest Anim Endocrinol， 2023， 3（1）：84-85.

组别	例数	miR-200a/U6			miR-152/U6
组别	例数	化疗前	化疗第1个疗程	化疗第3个疗程	化疗前	化疗第1个疗程	化疗第3个疗程
预后良好组	80	2.61 ± 0.59	2.21 ± 0.38^a	1.82 ± 0.33^ab	0.74 ± 0.19	0.82 ± 0.20^a	0.97 ± 0.21^ab
预后不良组	20	2.94 ± 0.64	2.54 ± 0.55^a	2.20 ± 0.40^ab	0.43 ± 0.16	0.55 ± 0.18^a	0.68 ± 0.17^ab
F值	-	F_交互 = 61.173、F_时间 = 42.990、F_组间 = 26.479			F_交互 = 16.880、F_时间 = 24.531、F_组间 = 106.537
P值	-	P_交互 < 0.001、P_时间 < 0.001、P_组间 < 0.001			P_交互 < 0.001、P_时间 < 0.001、P_组间 < 0.001

项目	例数	预后良好组（n=80）	预后不良组（n=20）	t/χ²值	P值
年龄［例（%）］				0.092	0.762
< 40岁	43	35（43.75）	8（40.00）
≥ 40岁	57	45（56.25）	12（60.00）
收缩压（mmHg）	-	125.42 ± 18.71	124.96 ± 17.42	0.100	0.921
舒张压（mmHg）	-	75.49 ± 10.16	75.88 ± 11.36	0.150	0.881
距前次妊娠间隔时间［例（%）］				0.260	0.610
< 7月	60	49（61.25）	11（55.00）
≥ 7月	40	31（38.75）	9（45.00）
前次妊娠性质［例（%）］				0.156	0.984
足月妊娠	15	12（15.00）	3（15.00）
流产	35	28（35.00）	7（35.00）
异位妊娠	12	10（12.50）	2（10.00）
葡萄胎	38	30（37.50）	8（40.00）
病灶数［例（%）］				0.174	0.677
< 5个	64	52（65.00）	12（60.00）
≥ 5个	36	28（35.00）	8（40.00）
病灶直径［例（%）］				0.097	0.756
< 5 cm	63	51（53.75）	12（60.00）
≥ 5 cm	37	29（36.25）	8（40.00）
临床分期［例（%）］				0.275	0.600
Ⅰ+Ⅱ	65	51（63.75）	14（70.00）
Ⅲ+Ⅳ	35	29（36.25）	6（30.00）
FIGO预后评分［例（%）］				14.527	< 0.001
< 7分	62	57（71.25）	5（25.00）
≥ 7分	38	23（28.75）	15（75.00）
化疗前血HCG水平［例（%）］				22.391	< 0.001
< 10 000 U/L	67	63（78.75）	4（20.00）
≥ 10 000 U/L	33	17（21.25）	16（80.00）

影响因素	B	SE	Wald χ²	OR	95%CI	P值
miR-200a	1.072	0.339	9.998	2.921	1.503 ~ 5.677	0.002
miR-152	-0.229	0.076	9.112	0.795	0.685 ~ 0.923	0.003
FIGO预后评分	1.089	0.326	11.164	2.972	1.569 ~ 5.630	0.001
化疗前血HCG水平	0.024	0.128	0.034	1.024	0.797 ~ 1.316	0.853

[1]	Xiaomei CHEN,Anqi WANG,Jizhen YANG,Miao YU. Prognosis and immune correlation analysis of m1A/m5C/m6A/m7G regulated genes in gastric cancer [J]. The Journal of Practical Medicine, 2024, 40(9): 1230-1237.
[2]	Shihe XIAO,Gang LI,Zhonghai LIU,Zhen. LIU. Expression of ZEB2 and CCL20 in glioma tissue and their correlation with prognosis [J]. The Journal of Practical Medicine, 2024, 40(9): 1262-1267.
[3]	Futao DANG,Yingmei TANG,Haiyan FU,Huanlong LI,Jiamin XU,Xu. TAN. The efficacy of artificial （nonbiological） extracorporeal liver support system for primary biliary cholangitis and the effect of this therapy on prognosis [J]. The Journal of Practical Medicine, 2024, 40(7): 955-961.
[4]	Xiya MA,Hu JI,Zehua ZHU,Bo PAN,Qiang XIE,Xiaobo. YAO. The predictive value of ¹⁸F⁃FDG PET/CT metabolic heterogeneity parameters combined with clinical features for the prognosis of esophageal squamous cell carcinoma before definitive radiochemotherapy [J]. The Journal of Practical Medicine, 2024, 40(7): 966-971.
[5]	Yuxin CHENG,Liang LIU,Shiyu DONG,Shengchao LI,Meng ZHANG. Research advances in exosomal proteins， mRNA and non⁃coding RNA regulation of Hepatocellular Carcinoma [J]. The Journal of Practical Medicine, 2024, 40(6): 748-755.
[6]	Junhong XU,Hongbing YAO,Xueyao WANG,Wei GUO,Caijin LU,Jiaxing WU,Jianhui JIANG,Dongkang ZHAO. Clinical efficacy of FOLFOX⁃HAIC combined with lenvatinib and PD⁃1 inhibitor in the treatment of intermediate and advanced Hepatocellular Carcinoma [J]. The Journal of Practical Medicine, 2024, 40(6): 762-767.
[7]	Yong LIU,XiaoLei CHENG,Xiangli CUI,Hao TANG,Huanzhen CHEN. ROBO3 deficiency promotes chemotherapy⁃induced transition of macrophage to foam cell [J]. The Journal of Practical Medicine, 2024, 40(6): 787-795.
[8]	Shu CHEN,Jinglei ZHANG,Kang RONG,Nan ZHANG,Weiyi SUN. Research progress of exosomes in distant metastasis and drug resistance of gastric cancer [J]. The Journal of Practical Medicine, 2024, 40(6): 870-876.
[9]	Sibo LONG,Yan CHEN,Xintong ZHANG,Yanjun YIN,Limei YANG,Maike ZHENG,Chaohong WANG,Qing SUN,Jun YAN,Yiheng SHI,Guangli SHI,Yan ZHAO,Guirong. WANG. Serum levels of procalcitonin， interleukin⁃6 and interleukin⁃8 in patients with COVID⁃19 infection at admission and their significance in patient prognosis [J]. The Journal of Practical Medicine, 2024, 40(4): 471-475.
[10]	Zixu SONG,Guangzheng ZHU,Chenxu GUO,Jiaqi WU,Ligong ZHANG,Jun. QIAN. Expression of SLC35A2 and PFDN2 in breast cancer and its relationship with clinical observables and prognosis [J]. The Journal of Practical Medicine, 2024, 40(4): 496-502.
[11]	Yichen WANG,Yanwen YAN,Meihui SONG,Xiangjun XUE,Wenguang ZHOU,Yuquan LI,Ling QI,Guanghua LI,Xiangzong ZENG. Clinical significance of HOXB4 gene expression levels in myelodysplastic syndromes [J]. The Journal of Practical Medicine, 2024, 40(3): 321-325.
[12]	Jia CUI,Mingming ZHANG,Na WANG,Wei GAO,Fei LI. Correlation analysis of glucose and lipid metabolism indicators combined with antiphospholipid antibodies on prognosis of patients with atherosclerosis [J]. The Journal of Practical Medicine, 2024, 40(3): 326-329.
[13]	Shuang CHEN,Na YANG,Yudong HUANG,Xiangfeng KONG,Jintao LI,Yizhong TANG,Kexiong MA,Yangyang ZHANG,Yuandong ZHANG,Chengde REN. Relationship between serum miR-21 and miR-27b levels and prognosis of patients with renal clear cell carcinoma [J]. The Journal of Practical Medicine, 2024, 40(3): 343-348.
[14]	Jian ZHAO,Songjie LIU,Guanchao ZHANG,Yuhou SHEN,Fengchen LI,Bing XU. Expression of CENPF and miR⁃1⁃3p in the serum of patients with advanced gastric cancer and their correlation with prognosis [J]. The Journal of Practical Medicine, 2024, 40(3): 365-370.
[15]	Zhijie XIA,Jun LI,Qian GAO,Zhicheng LI,Zhongfang. XIA. Effect and prognosis of preauricular fistula treated by double⁃incision tunnel combined with preauricular tissue and cartilage resection [J]. The Journal of Practical Medicine, 2024, 40(22): 3179-3183.

The relationship between serum levels of miR⁃200a and miR⁃152 and the prognosis of patients with gestational trophoblastic neoplasia undergoing chemotherapy

RichHTML

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

Figures/Tables 5

References 25

Related Articles 15

Recommended Articles

Metrics

Comments